



Tumor Microenvironment: From Cellular Components to Therapeutic Perspectives

Guest Editors:

Dr. Adriana Grigoraș

Department of Morphofunctional Sciences, “Grigore T. Popa” University of Medicine and Pharmacy, University Street No. 16, Iasi, Romania

Prof. Dr. Cornelia Amalinei

Department of Morphofunctional Sciences I, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

Deadline for manuscript submissions:

closed (30 November 2023)

Message from the Guest Editors

Dear Colleagues,

The tumor microenvironment is a complex ecosystem, which includes cancer-associated cells, blood vessels, and extracellular matrix, involving a large panel of cellular-derived factors. It also comprises different types of immune cells, such as T and B lymphocytes, natural killer (NK) cells, dendritic cells, myeloid-derived suppressor cells (MDSCs), neutrophils, and tumor-associated macrophages (TAMs). In addition, intercellular communication is supported by a large spectrum of chemokines, cytokines, inflammatory mediators, growth factors, and matrix-remodeling enzymes in the tumor niche.

For this Special Issue of Biomedicines, we invite authors to submit contributions that provide new insights into the mechanisms of tumor microenvironment contribution to cancer development, progression, metastasis, immune escape, and therapy resistance. In particular, articles or reviews on new findings or concepts regarding the cellular and molecular interactions between tumor cells and microenvironment components, as well as their cooperation in tumor invasion and therapy resistance, are of great interest.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)